Work

Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial

Year: 2024

Type: article

Study design: Clinical Trial

Source: European Urology Oncology

DOI: 10.1016/j.euo.2024.06.013

Authors: Tian Zhang, Lauren Howard, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart A. Frizzell, Luke Nordquist, Julia Rasmussen, Colleen Riggan, Marco Reyes, Catrin Davies, Steven R. Gray, Carly R. Newman, Escarleth Fernandez, Sundhar Ramalingam, Michael R. Harrison, Daniel J. George, Yuan Wu, Andrew J. Armstrong

Institutions: Duke University, Duke Cancer Institute, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, East Carolina University, Weill Cornell Medicine, Atrium Health Wake Forest Baptist

Language: English

Topic: Prostate Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: U.S. Department of Defense, Prostate Cancer Foundation, Janssen Scientific Affairs, Weill Cornell Medicine, Janssen Pharmaceuticals, Duke Cancer Institute

Awards: G1921916957, PCRP CLINICAL CONSORTIUM: DUKE UNIVERSITY CLINICAL RESEARCH SITE, G3052100970, G6207543738, G704522546

OpenAlex ID: W4400360314

FWCI: 0.577

Cites: 19

Cited by: 2

Related to: 10